Skip to content

Clinical trials

Diabetes, Gestational trials in Canada with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes, Gestational Phase: Not applicable Country / region: Canada Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20102
20111
20123
20144
20151
20162
20192
20201
20221
20231
20242
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Active, not recruiting5
Recruiting3
Unknown status3
Terminated2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
McGill University Health Centre/Research Institute of the McGill University Health Centre4
Ottawa Hospital Research Institute2
Samuel Lunenfeld Research Institute, Mount Sinai Hospital2
Université de Sherbrooke2
CHU de Quebec-Universite Laval1
IWK Health Centre1
Laval University1
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's1
McGill University1
McMaster University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes, Gestational24
Diabetes Mellitus, Type 25
Diabetes Mellitus2
Breast Neoplasms1
Cardiovascular Diseases1
Gestational Weight Gain1
Hypertension, Pregnancy-Induced1
Insulin Resistance1
Metabolic Syndrome1
Obesity1

Trials

Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.